Autopsy report · NCT04370522

Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer

“Lack of funding to continue the research into Phase II”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 1 month before it started.
• Ran for about 3 years 10 months before it stopped.
• 32 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Spanish Breast Cancer Research Group

Sponsor type

University, hospital or other

Conditions

Metastatic Breast Cancer

Participants

32

Sites

2

Countries

Spain

Trials that died the same way

• Trial of Topical Verapamil in Chronic Rhinosinusitis With Nasal Polyps
  “Phase II funding not available” (77% match in meaning)
• Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
  “Due to lack of funding, phase II of study was not completed.” (72% match in meaning)
• Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies
  “Lack of funding and change in research direction.” (72% match in meaning)
• Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
  “Lost funding for Phase II portion of study” (71% match in meaning)
• Efficacy of Kerecis Omega 3 in Comparison to Clinical Standard Procedures
  “Lack of funding to support the study” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.